Protalix Biotherapeutics, Inc. (PLX)

Protalix Biotherapeutics' stock price has fluctuated in the past six months. While the stock experienced a 6.71% increase in the past month, it fell 21% in October 2025 and 17% in November 2025. Key events include Q3 2025 earnings report missing analyst forecasts, EMA negative opinion for Elfabrio, Q2 and Q1 2025 earnings reports showing revenue increases, and legal investigations announced by Pomerantz LLP and Levi & Korsinsky.

Specific data on demand seasonality for Protalix Biotherapeutics' products is not extensively detailed. Global ordering patterns for Elfabrio are expected to fluctuate quarterly during its early launch phase. Investing.com offers tools to analyze mean and median monthly returns for PLX to identify seasonal patterns. The nature of rare disease treatments often implies a more consistent demand driven by patient need rather than seasonal variations.

Protalix Biotherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx® plant cell-based protein expression system. Their main products include Elelyso® for Gaucher disease and Elfabrio® for Fabry disease, with a pipeline including PRX-115 for gout and PRX-119 for NETs diseases.

Protalix Biotherapeutics is headquartered in Carmiel, Israel, with operations in the United States. It has partnerships with global pharmaceutical companies like Pfizer and Chiesi Farmaceutici S.p.A., and its products and pipeline candidates have a global reach, including markets in Australia, Canada, Brazil, Russia, and Turkey.

Protalix Biotherapeutics has a reputation as a pioneering biopharmaceutical company focused on developing innovative protein solutions for rare diseases. The company was the first to gain FDA approval for a protein produced through a plant cell-based expression system. However, the company's reputation has been affected by a negative opinion from the EMA regarding an Elfabrio dosing regimen and legal investigations by law firms on behalf of investors.

Protalix Biotherapeutics, Inc. has a diverse ownership structure, including institutional, insider, and retail investors. Institutional shareholders hold 17.31% of the stock, while insiders hold 169.79%. Major institutional owners include BlackRock, Inc., Opaleye Management Inc., and iShares Russell 2000 ETF (IWM). Biocell Ltd is the largest individual shareholder, owning 37.85% of the company. Insider sentiment has been positive, with $5.95 million in purchases over the last year, but insiders have sold more shares than they have bought in the past three months.